Lantern Pharma, Inc

Industry

  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
See more in Biomedtracker

Latest on Lantern Pharma, Inc

Scrip

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie, Gilgamesh To Investigate Potent

Scrip

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

Scrip

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

 
• By Joseph Haas, Vibha Ravi, and Mandy Jackson

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E

Scrip

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

 
• By Joseph Haas and John Davis

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’